Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Chemotherapy and Radiotherapy
  •  Brain and Spinal Cord Cancer
  •  Carcinomas
  •  Haemato-Oncology
  •  Endometrial Cancer
  •  Endoscopy Methods
  •  Hormone Therapy
  •  Pancreatic Cancer


Citation: Clin Oncol. 2021;6(1):1824.DOI: 10.25107/2474-1663.1824

Personalized Thera(g)nostic Approach in Patients with Paraganglioma: Peptide Receptor Radionuclide Therapy

Bernhard Nilica, Hanna Svirydenka, Christian Mair, Alexander Stephan Kroiss, Michael Gabriel and Irene Virgolini

Department of Nuclear Medicine, Medical University Innsbruck, Austria
Institute of Nuclear Medicine and Endocrinology, Kepler University Hospital, Linz, Austria

*Correspondance to: Bernhard Nilica 

 PDF  Full Text Research Article | Open Access


Objective: The experience with Somatostatin-Receptor (SSTR) based Peptide-Radionuclide Therapy (PRRT) in patients with Paraganglioma (PGL) is limited. We report our experience for the treatment of malignant PGL. Material and methods: Nineteen patients with PGL, who were treated with 90Y-DOTATOC/177Lu-DOTATATE, were  retrospectively reviewed. Response to treatment was evaluated by RECIST 1.0/PERCIST 1.1 criteria.
Results: Of the 19 patients, 6 were male and 13 females, ages ranged from 18 to 74 years at initial diagnosis. Pre-therapeutic scanning was positive in 19/19 PGL-patients with 68Ga-DOTATOC from whom 13/19 patients received 90Y-DOTATOC (ACA (accumulated activity) range 8.07-16.44 GBq, ATD (accumulated tumour dose) range 4.6 Gy to 152.8 Gy), 4/19 patients 177Lu-DOTATATE (ACA range 8.49 GBq to 55.42 GBq, ATD range 14.1 Gy to 235.3 Gy). In two patients no therapy could be applied. The median PFS and OS was 96 (range 10 to 180) and 99.5 (range 24 to 180) months, respectively.
Conclusion: Both 90Y/177Lu-SSTR-targeting peptides may be useful for long-term disease control in patients with locally advanced or metastatic paraganglioma when applied in several treatment cycles that may reach meaningful absorbed tumour doses. Pretherapeutic scanning for a tailored treatment regimen seems appropriate in order to identify the radiopharmaceutical with highest tumour uptake.


Paraganglioma; 131I-mIBG; Somatostatin; PRRT

Cite the Article:

Nilica B, Svirydenka H, Mair C, Stephan Kroiss A, Gabriel M, Virgolini I. Personalized Thera(g)nostic Approach in Patients with Paraganglioma: Peptide Receptor Radionuclide Therapy. Clin Oncol. 2021;6:1824..

Search Our Journal

Journal Indexed In

Articles in PubMed

LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

NLRP3 Inflammasome Enhances Tumor Growth
 Abstract  PDF  Full Text
Minimally Invasive Non-Endoscopic Thyroidectomy with a Low Anterior Cervical Incision
 Abstract  PDF  Full Text
View More...